Jonathan Milner, co-founder of Abcam, offers a masterclass in building successful life science starts-ups, based on his experience with over 40 companies and three Tech IPOs on the London AIM Stock Exchange.
Jonathan will be looking at the bigger picture trends and breakthroughs in life sciences and then explain how he is trying to translate this exciting science into businesses. His particular areas of interest include stem cell technology; new approaches to drug discovery; genomics and proteomics big data; and diseases of ageing and the ageing process.
Jonathan cofounded Abcam when working as a postdoctoral researcher studying the newly discovered breast cancer protein BRCA2 in Kouzarides' Cambridge University laboratory. Now a listed e-commerce company providing antibodies and other protein research tools to a global market, it encourages and publishes product reviews and ratings submitted by customers.
Horizon Discovery designs and engineers genetically modified cells, applying them in research and clinical applications that advance human health.
Dr. Jonathan Milner, Deputy Chairman, Abcam plc
Background: Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with Dr David Cleevely and Professor Tony Kouzarides.
Current external appointments: Jonathan is a Non-Executive Director of Horizon Discovery Group plc, The Evolution Education Trust, Repositive Ltd, Syndicate Room Group Ltd and HealX. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Definigen Limited and CamAllergy Ltd. Jonathan holds an Executive Director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP, and is a member of the Advisory Panel of Cambridge Innovation Capital plc.
Skills and experience: Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three AIM IPOs.
Sarah Madden - Stabilising Omomyc - a new cancer drug